



Konstantinos N. Syrigos, MD, PhD, FCCP

Professor of Medicine & Medical Oncology,
Head, 3rd Department of Medicine, Athens School of Medicine,
National & Kapodistrian University of Athens (NKUA), GR.

Professor of Thoracic Oncology, Yale School of Medicine, CT, USA.

BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
Kostas Syrigos, MD, PhD, FCCP	Professor & Head 3 rd Department of Medicine, Athens School of Medicine National & Kapodistrian University of Athens, (NKUA), GR.

EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD OF STUDY
Athens School of Medicine	MB BS	1988	Medicine
Athens School of Medicine	MD	1995	Medicine-endocrinology
Imperial College of Science & Medicine, London Univ., UK	MPhil, PhD	2002	Immuno-oncology
Laikon University Hospital, Athens, Greece			Internal Medicine
Hammersmith Hospital, London, UK			Medical Oncology

A. Positions and Honors.

- Chair, Faculty of Medicine, School of Medicine, National & Kapodistrian University of Athens, Greece, 2019-Present.
- Chairman of the Board of Directors of SOS Children's Villages Greece, 2018-Present.
- Member of the ESMO Lung Cancer Faculty, Lausanne, Switzerland, 2016-Present.
- Head, 3rd Department of Medicine, School of Medicine, National & Kapodistrian University of Athens, Greece, 2014-Present.
- Professor of Medicine & Medical Oncology, National & Kapodistrian University of Athens, Greece, 2013-Present
- Visiting Professor of Thoracic Oncology, Yale University School of Medicine, Yale Cancer Center, CT, USA. 2006-Present.
- Consultant and Head, Oncology Unit, 3rd Dept of Medicine, Sotiria General Hospital, Athens, Greece. 2000-Present.

B. Scientific Metrics

Total peer review international publications: >650
 Total chapters in international scientific volumes: >100
 Citations: >25.000 h-index: 72

C. Editor of International Scientific Volumes

1. ERLOTINIB IN LUNG CANCER: IMPACT & EXCEPTIONAL CASES
 Editors: Konstantinos N. Syrigos
 Publisher: Focus on Health Ltd. Publications, Athens 2014
2. BEVACIZUMAB IN LUNG CANCER: IMPACT & EXCEPTIONAL CASES
 Editors: Konstantinos N. Syrigos
 Publisher: Focus on Health Ltd, Athens 2013
3. ESMO GLOSSARY OF TRANSLATIONAL RESEARCH
 Editors: ESMO Translational Research Group
 Publisher: ESMO Press, November 2012.

4. THORACIC ONCOLOGY ATLAS
Editors: Giannis Giozos, Adriani Charpidou, KN Syrigos
Publisher: Parisianos Publications, February 2012.
5. HARRISON HEMATOLOGY & ONCOLOGY, Greek Edition
Editors: Dan L. Longo, KN Συρίγος
Publisher: Parisianos Publications, February 2011.
6. TUMORS OF THE CHEST: BIOLOGY, DIAGNOSIS AND MANAGEMENT
Editors: Konstantinos N. Syrigos, Christopher Nutting, Ch. Roussos.
Publisher: Springer, New York, 2006, pages 460.
7. TARGETED THERAPY OF CANCER
Editor: Konstantinos N. Syrigos, Kevin J Harrington.
Publisher: Oxford University Press, London, 2003, pages 343.
8. IMMUNOLOGY FOR SURGEONS
Editors: Andrew Zbar, Kirk Bland, Konstantinos N. Syrigos,
Publisher: Springer-Verlang, London, 2002, pages 464
9. PROSTATE CANCER: BIOLOGY, DIAGNOSIS AND MANAGEMENT
Editor: Konstantinos N. Syrigos,
Publisher: Oxford University Press, London, 2001, pages 479.
10. BLADDER CANCER: BIOLOGY, DIAGNOSIS AND MANAGEMENT
Editors: Konstantinos N. Syrigos, Donald R. Skinner.
Publisher: Oxford University Press, London, 1999, pages 469.
11. AIDS AND MALIGNANCIES: CURRENT CONCEPTS AND PERSPECTIVES.
Editors: B Golematis, Vincent T. DeVita Jr, K.N. Syrigos, M. Konstadoulakis.
Publisher: John Wileys & Sons Ltd, London, 1996.

D. Selected peer-reviewed publications

2020

1. Dimou A, Syrigos KN.
The Role of GSK3 β in T Lymphocytes in the Tumor Microenvironment
Front Oncol. 2020 Jul 24; 10:1221.
2. Gerotziafas G, Mahé I, Lefkou E, Abo Elnazar E, Abdel-Razeq H, Taher A, Antic D, Elalamy I, Syrigos KN, Van Dreden P.
Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer
Thromb Res. 2020 Jul;191 Suppl 1: S50-S57.
3. Kollias A, Kyriakoulis KG, Stergiou GS, Syrigos KN.
Heterogeneity in reporting venous thromboembolic phenotypes in COVID-19: methodological issues and clinical implications
Br J Haematol. 2020 Jul 4;10.1111/bjh.16993.
4. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos KN, GRECCO-19 investigators.
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
JAMA Netw Open. 2020 Jun 1;3(6):e2013136.
5. Kollias A, Kyriakoulis KG, Destounis A, Stergiou GS, Syrigos KN.
Letter to the Editor – Cardiac injury and prognosis in COVID-19: Methodological considerations and updated meta-analysis
J Infect. 2020 Jun 17;S0163-4453(20)30413-8.
6. Toki MI, Harrington K, Syrigos KN.
The Role of Spread Through Air Spaces (STAS) in Lung Adenocarcinoma Prognosis and Therapeutic Decision Making
Lung Cancer. 2020 May 12;146:127-133.
7. Grapsa D, Syrigos KN.
Direct KRAS Inhibition: Progress, Challenges, and a Glimpse Into the Future Editorial Expert Rev Anticancer Ther. 2020 Apr 28;1-4.

8. [Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos KN.](#)
Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action
Br J Haematol. 2020 Jun;189(5):846-847.
9. [Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, Korozan M, de Las Penas R, Majem M, Chella A, Griesinger F, Bournakis E, Sadjadian P, Kotsakis A, Chinnet T, Syrigos KN, Correale P, Gallou C, Jamet JM, Vetsika EK, Kosmatopoulos K, Georgoulis V, Vx-001-201 trial team.](#)
Clinical Activity of a Htert (vx-001) Cancer Vaccine as Post-Chemotherapy Maintenance Immunotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Final Results of a Randomised Phase 2 Clinical Trial
Br J Cancer. 2020 May;122(10):1461-1466.
10. [Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C.](#)
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbeopetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol. 2020 Feb ;15(2):190-202.

2019

11. [Linardou H, Kotoula V, Kouvatseas G, Mountzios G, Karavasili V, Samantas E, Kalogera-Fountzila A, Televantou D, Papadopoulou K, Mavropoulou X, Daskalaki E, Zaramboukas T, Efstratiou I, Lampaki S, Rallis G, Res E, Syrigos KN, Kosmidis PA, Pectasides D, Fountzilias G.](#)
Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment.
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):531-541
12. [Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Fridmott-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators.](#)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019 Oct 4;20(12):1655-1669.
13. [Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos KN, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.](#)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med. 2019 Sep 28.
14. [Villaruz LC, Cobo M, Syrigos KN, Mavroudis D, Zhang W, Kim JS, Socinski MA.](#)
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Lung Cancer. 2019 Aug 14;136:52-56.
15. [Dimou A, Bamias A, Gogas H, Syrigos KN.](#)
Inhibition of the Hedgehog pathway in lung cancer.
Lung Cancer. 2019 Jul;133:56-61.
16. [Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL.](#)
High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling.
Clin Cancer Res. 2019 Jun 12;25(18):5503-5512
17. [Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos KN, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.](#)
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Clin Cancer Res. 2019 May 3;25(15):4663-4673
18. [Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos KN, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A.](#)
Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.
Clin Cancer Res. 2019 Mar 1, 25(5):1526-1534.

2018

19. [Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hirt S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.](#)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med. 2018 Dec 13, 379(24):2342-2350.
20. [Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group.](#)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med. 2018 Dec 6, 379(23):2220-2229.

21. Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. *J Thorac Oncol.* 2018 Dec, 13(12):1884-1896.
22. Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos KN, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. *JAMA Oncol.* 2018 Dec 1, 4(12):e183486.
23. Syrigos KN, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergeantanis TN, Elalamy I, Falanga A, Gerotziakas GT. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. *Oncologist.* 2018 Nov, 23(11):1372-1381.
24. Goss GD, Felip E, Cobo M, Lu S, Syrigos KN, Lee KH, Göker E, Georgoulas V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. *JAMA Oncol.* 2018 Sep 1, 4(9):1189-1197.
25. Syrigos KN, Georgoulas V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. *Anticancer Res.* 2018 Jun, 38(6):3735-3744.
26. Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. *J Thorac Oncol.* 2018 Aug, 13(8):1076-1082.
27. Magkrioti C, Oikonomou N, Kaffe E, Mouratis MA, Xylourgidis N, Barbayianni I, Megadoukas P, Harokopos V, Valavanis C, Chun J, Kosma A, Stathopoulos GT, Bouros E, Bouros D, Syrigos KN, Aidinis V. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis. *Cancer Res.* 2018 Jul 1, 78(13):3634-3644.
28. Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos KN, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA. Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2018 Apr 1, 24(7):1562-1573.

2017

29. Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos KN, Arrieta O, Prabhaskar K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Carter GC, Alexandris E, Garon EB. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. *Lung Cancer.* 2017 Oct, 112:126-133.
30. Meyer M, Vliegthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos KN, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED. Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies. *J Thorac Oncol.* 2017 Dec, 12(12):1755-1765.
31. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiet S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med.* 2017 Nov 16, 377(20):1919-1929.
32. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *N Engl J Med.* 2017 Jun 22, 376(25):2415-2426.
33. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med.* 2017 Aug 31, 377(9):829-838.
34. Gadgeel S, Goss G, Soria JC, Felip E, Georgoulas V, Lu S, Cobo M, Syrigos KN, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A. Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. *Lung Cancer.* 2017 Jul;109:101-108.

35. Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos KN, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. *Clin Cancer Res.* 2017 Sep 1, 23(17):5202-5209.
36. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos KN, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. *J Thorac Oncol.* 2017 Feb, 12(2):194-207.

2016

37. Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Nowak A, Rusch VW; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. *J Thorac Oncol.* 2016 Dec, 11(12):2082-2088.
38. Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. *J Thorac Oncol.* 2016 Nov, 11(11):1901-1911.
39. Matikas A, Syrigos KN, Agelaki S. Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. *Clin Lung Cancer.* 2016 Nov, 17(6):507-516.
40. Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and participating institutions. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. *J Thorac Oncol.* 2016 Dec, 11(12):2100-2111.
41. Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. *J Thorac Oncol.* 2016 Dec, 11(12):2089-2099.
42. Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. *J Thorac Oncol.* 2016 Dec, 11(12):2112-2119.
43. Pérol M, Ciuleanu TE, Arrieta O, Prabhaskar K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. *Lung Cancer.* 2016 Mar, 93:95-103.

2015

44. Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, **Syrigos KN**, Shen L, Chadja M, Wolf M. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. *J Thorac Oncol.* 2015 Aug, 10(8):1221-8.
45. Konstantakou EG, Voutsinas GE, Velentzas AD, Basogianni AS, Paronis E, Balafas E, Kostomitsopoulos N, **Syrigos KN**, Anastasiadou E, Stravopodis DJ. 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants. *Mol Cancer.* 2015 Jul 22, 14:135.
46. Soria JC, Felip E, Cobo M, Lu S, **Syrigos KN**, Lee KH, Göker E, Georgoulas V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD, LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol.* 2015 Aug, 16(8):897-907.
47. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Leticic A, Kurek R, Paz-Ares L, Socinski MA, **SQUIRE Investigators**.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Lancet Oncol. 2015 Jul, 16(7):763-74.

48. Eberhardt WE, De Ruyscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S, **Panel Members**. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015 Aug, 26(8):1573-88.
49. Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, **Syrigos KN**, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PLoS One. 2015 May 13, 10(5):e0124612.
50. Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA, **INSPIRE investigators**. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar, 16(3):328-37.

2014

51. Dimou A, Non L, Chae YK, Tester WJ, **Syrigos KN**. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 2014 Sep 18, 9(9):e107677.
52. Garon EB, Ciuleanu TE, Arrieta O, Prabhaskar K, **Syrigos KN**, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23, 384(9944):665-73.
53. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip E; Panel Members, **Panel Members**. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014 Sep, 25(9):1681-90.
54. Vansteenkiste J, Crino L, Doooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E, **Panel Members**. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014 Aug, 25(8):1462-74.
55. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA, **START trial team**. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan, 15(1):59-68.
56. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, **Syrigos KN**, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014 Jan, 94(1):107-16.
57. Ntikoudi E, Kiagia M, Boura P, **Syrigos KN**. Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev. 2014 Feb, 40(1):22-30.